Navigation Links
Heptares to Moderate Panel on Rare Diseases at BBC New York CEO Meeting (13-14 February)
Date:2/8/2013

WELWYN GARDEN CITY, England and BOSTON, February 8, 2013 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery company, announces that its President, Dan Grau , will attend the Boston Biotech Conference New York CEO Meeting taking place on 13-14 February at Apella in New York City, NY, USA, at which he will moderate a panel on Rare Diseases (3:30pm EST, 14 February).

For a full list of events at which Heptares will be present, please visit http://www.heptares.com

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, AstraZeneca, MedImmune, Takeda and Cubist, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com.


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
2. Heptares Solves First Family B GPCR Structure
3. Heptares to Present at BIO-Europe 2012
4. Ali Velshi To Moderate The Food Dialogues (SM): New York On Nov. 15
5. Lucintel Estimates Moderate Growth for Global Pulp and Paper Chemical Industry during 2012-2017
6. Urologists Outraged over Government Panels Recommendation to Stop Life-Saving Prostate Cancer Testing
7. OBN Adds World Class Pharma and VC Figures to its Thematic Advisory Panels
8. NSF awards $450,000 to UNH, Conductive Compounds Inc. for solar panel innovation
9. WaferGens MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
10. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
11. Researchers Identify New Regulator in Allergic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), ... novel therapies for metabolic and endocrine disorders, today announced ... Ph.D., will deliver a corporate presentation at H.C. Wainwright ... being held April 3, 2017 at the St. Regis ... this presentation are as follows: ...
(Date:3/28/2017)... 28, 2017 Focus is ... sector due to the scientifically intensive operations of ... agricultural, environmental, and industrial. In today,s pre-market research, Stock-Callers.com ... Inc. (NASDAQ: PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera ... (NASDAQ: OCUL ). Learn more about ...
(Date:3/27/2017)... -- Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company ... foodborne pathogens,  today announced that Mary Duseau , CEO ... on March 29 at 9:50am ET. The conference will be ... About Roka Bioscience ... Roka Bioscience is a molecular diagnostics company ...
(Date:3/27/2017)... Md. , March 27, 2017  The ... billion for 2016, according to a new report ... medical lab testing is performed to evaluate disease ... individual therapy, among other reasons.  The healthcare market ... Market , provides an overview of the ...
Breaking Biology Technology:
(Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):